Given that FAD mutations were only detected in < 2 % of AD cases, and hypoperfusion was identified in a majority of preclinical AD patients without detectable amyloid pathology, an eNOS+/- model is more representative of sporadic AD cases and is predictably useful for studying early pathogenic mechanisms. The gene discussed is NOS3; the disease is amyloidosis.